Lixia Qiu

Lixia Qiu

Auto-generated profile, based on publicly available information

Lixia Qiu

Department of Health Statistics, School of Public Health, Shanxi Medical University, Taiyuan, Shanxi 030001, PR China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 June 2025 in International Journal of Pharmaceutics
Verified
Journal Article
Open access
YQYuchao Qiao
Yuchao Qiao
SKShuhui Kang
Shuhui Kang
YWYijia Wu
Yijia Wu
YCYu Cui
Yu Cui
XWXuchun Wang
Xuchun Wang
LQLixia Qiu
Lixia Qiu
Polycaprolactone microspheres (PCL-MS) are widely used in tissue filling, while particle size and uniformity are crucial for improving filling and therapeutic effects. Efficient optimization methods are essential for accelerating their development. Box-Behnken design was applied to investigate three factors for PCL-MS: PCL concentration (X1), polyvinyl alcohol concentration (X2) and water-oil ratio (WOR,X3). Mathematical models were developed to predict particle size (Y1) and particle size distribution width (Y2). Multi-objective optimization of Y1 and Y2 was performed using the Nondominated Sorting Genetic Algorithm-II (NSGA-II) and the Multi-Objective Artificial Hummingbird Algorithm (MOAHA) to determine the optimal preparation schemes. Experimental validation was conducted to confirm the validity and reliability of the optimization schemes. After multi-objective optimization, two ideal preparation schemes were selected from the Pareto solution sets obtained by NSGA-II and MOAHA, respectively. Experimental validation showed no significant statistical difference (P>0.05) between the measured and predicted values of Y1 and Y2 for scheme 12 and 21 of NSGA-II and scheme 3 of MOAHA, with deviations under 5%. All protocols met target requirements, indicating their suitability for PCL-MS preparation. This study utilized Box-Behnken design and intelligent optimization to develop three alternative PCL-MS formulations, facilitating the production of microspheres with smaller particle sizes and narrower distributions, thereby advancing formulation development.